|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adoptive transfer of HER2-specific CAR-T cells resulted in the regression or even elimination of CRC xenograft and protection of relapse from rechallenged colon cancer tissue in PDX model.
|
30586347 |
2020 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have used SW48 and LIM1215 human colon cancer cell lines, quadruple wild-type for KRAS, NRAS, BRAF and PI3KCA genes, and their HER2-amplified (LIM1215-HER2 and SW48-HER2) derived cells to perform in vitro and in vivo studies in order to identify novel therapeutic strategies in HER2 gene amplified human colorectal cancer.
|
31164152 |
2019 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results indicates that <sup>125</sup>I-Herceptin can be considered as an effective SPECT probe for the non-invasive detection of HER2 expression in colon cancer.
|
30217443 |
2018 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our results suggest that inhibition of Nrf2 signaling in colon cancer patients with Her2 overexpression can be considered as an important strategy to overcome oxaliplatin resistance.
|
29684854 |
2018 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Areas covered: The present review summarizes the current progress and future directions for HER2 targeted therapies in GI cancers, including esophagogastric, pancreaticobiliary, and colon cancers.
|
30092682 |
2018 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
CNVs in DCC/18q and ERBB2/17q are significantly associated with DFS in Stage II-III MSS colon cancer.
|
28006840 |
2017 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Structure-based design of peptides against HER2 with cytotoxicity on colon cancer.
|
27068253 |
2017 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2 gene is located on chromosome 17 and is amplified in a subset of cancers, such as breast, gastric, and colon cancer.
|
26435392 |
2015 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The obtained data highlight the crucial importance of EGF on the expression of both receptors and on the EGF-EGFR/HER2 signaling network, reveal the distinct roles of EGFR and HER2 on expression of matrix macromolecules and open a new area in designing novel agents in targeting colon cancer.
|
24792576 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the significance of HSP90 and Her2 expression in colon cancer.
|
24733427 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer therapy.
|
24970817 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated effects of EGFR and HER-2 blockade in colon cancer cell lines using cetuximab and trastuzumab, with the aim of developing novel approaches to cancer therapy.
|
25131935 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biomarkers such as HER2 for breast cancer or EGFR mutation for lung cancer and KRAS mutation in colon cancer have contributed to identify a patient population that might show a good and bad treatment response, respectively.
|
21652149 |
2012 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Forty-eight-hour treatment of colon cancer HCT-116 and HT-29 cells with FOLFOX resulted in 60-70% survival, accompanied by a marked activation of insulin like growth factor-1 receptor (IGF-1R) and minor to moderate increase in epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2) as well as v-akt murine thymoma viral oncogene homolog 1 (AKT), cyclooxygenase-2 (COX-2) and cyclin-D1.
|
20332435 |
2010 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The EGFR and HER2 proteins were overexpressed and constitutively activated in all of the colon cancer cell lines when compared with the FHC cell line.
|
15814656 |
2005 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
ErbB2 and ErbB3 receptor tyrosine kinases have been associated with the development of human colon cancer, and the expressions of both receptors are high in HT-29 cells.
|
15741050 |
2005 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Colon cancer cell lines constitutively expressed HER-2 proteins and none showed HER-2 amplification by fluorescence in situ hybridization.
|
14696118 |
2004 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have evaluated HER 2/neu gene amplification and protein overexpression in a series of colon cancers to assess the frequency, concordance and clinical significance of these events.
|
12767065 |
2003 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines.
|
9413188 |
1998 |